ellievsbear
we're not kids anymore.
cherry valley forever
Product Placement
pixel skylines
let's talk about Bridgerton tea, my ask is open
RMH
Aqua Utopia｜海の底で記憶を紡ぐ
Jules of Nature
roma★
One Nice Bug Per Day
Alisa U Zemlji Chuda
NASA
Stranger Things
Cosmic Funnies
blake kathryn
Game of Thrones Daily
Lint Roller? I Barely Know Her
noise dept.
Discoholic 🪩
seen from India
seen from Cambodia
seen from Italy
seen from Japan
seen from United States
seen from Ireland
seen from United Kingdom
seen from United Kingdom
seen from Japan
seen from Australia
seen from Australia
seen from Brazil
seen from United States
seen from Türkiye
seen from Malaysia
seen from Malaysia
seen from Germany
seen from United Kingdom
seen from United States
seen from Italy
@emergencydrug
Osimertinib (Osimert) 80 mg
Osimertinib (Osimert) is a inhibitor indicate for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who progress on or after EGFR TKI therapy.
Tofacinix is treatment of moderate to severe ulcerative colitis, polyarticular juvenile arthritis, rheumatoid arthritis, psoriatic arthritis
Xeljanz is an oral, small-molecule medication used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular
Tofacent is used for treating moderate to severe rheumatoid arthritis (RA). This helps reduce pain, tenderness, and swelling in the joints
Tagrix indicate for the prevent epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Tagrix (Osimertinib) protect the epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Osimert (Osimertinib) is a Capsule use to treat of epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cance
Osimertinib Mechanism of Action
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). Its primary mechanism of action involves targeting and inhibiting the activity of epidermal growth factor receptor (EGFR) tyrosine kinase. Here's a breakdown of its mechanism of action:
EGFR Inhibition: Osimertinib specifically targets mutant forms of the EGFR protein. In NSCLC, mutations in the EGFR gene are relatively common, and they can drive the growth of cancer cells. Osimertinib selectively inhibits both activating mutations in EGFR (exon 19 deletions or L858R mutations) and the T790M resistance mutation.
Irreversible Binding: Unlike some earlier-generation EGFR TKIs, Osimertinib irreversibly binds to the EGFR kinase domain. This irreversible binding helps to prolong the inhibitory effect on the receptor.
Mutant-Selective Action: Osimertinib is designed to selectively inhibit mutant forms of EGFR while sparing the normal, wild-type EGFR. This selectivity is crucial in reducing the side effects associated with the inhibition of wild-type EGFR, which is important for normal cellular function.
T790M Resistance Mutation: Osimertinib is particularly effective against NSCLC tumors that have developed resistance to first- and second-generation EGFR TKIs due to the T790M mutation. This mutation often emerges as a resistance mechanism during treatment with earlier EGFR inhibitors.
Some Osimertinib genetic product.
Discover the cost of Tofacitinib 11 mg and explore pricing options for this effective medication. Tofacinix 11 mg tablet prescribed for auto
Tofacitinib mechanism of action
Tofacitinib is a medication used to treat certain autoimmune diseases, primarily rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Its mechanism of action involves targeting specific molecules and pathways in the immune system to reduce inflammation and modulate the immune response. Here's an overview of how tofacitinib works:
Janus Kinase (JAK) Inhibition: Tofacitinib drug belongs to a class of known as Janus Kinase (JAK) inhibitors. JAKs are enzymes that play a crucial role in transmitting signals within immune cells. By inhibiting specific JAK enzymes, tofacitinib interferes with the signaling pathways that lead to inflammation and immune system activation.
Cytokine Inhibition: JAK enzymes are involved in the signaling of various cytokines, which are small proteins that regulate immune responses. Tofacitinib primarily inhibits JAK1 and JAK3, which are associated with signaling by cytokines like interleukin-6 (IL-6), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-15 (IL-15), and interferon-gamma (IFN-gamma). By blocking these cytokine signals, tofacitinib helps reduce inflammation and control immune system activity.
Immune System Modulation: Tofacitinib helps modulate the immune response by reducing the activity of certain immune cells, particularly T cells and B cells, which are involved in autoimmune diseases. It can also affect other immune cells like natural killer (NK) cells and dendritic cells.